66
Participants
Start Date
December 31, 2007
Primary Completion Date
April 30, 2018
Study Completion Date
April 30, 2018
Moroctocog alfa (AF-CC)
On-demand therapy for 6 months, followed by routine prophylaxis 25 IU/kg, administered every other day for 1 year.
Moroctocog alfa (AF-CC)
"Routine prophylaxis crossover:~45 IU/kg, administered 2 times a week for 1 year followed by 25 IU/kg administered every other day for 1 year, or, 25 IU/kg, administered every other day for 1 year, followed by 45 IU/kg, administered 2 times a week for 1 year."
Sultan Qaboos University Hospital, Muscat
Medizinische Universitaet Wien, Vienna
Christchurch Hospital, Christchurch
Canterbury District Health Board, Christchurch
Clinical Hospital Centre Split, Split
Jordan University of Science and Technology, King Abdullah University Hospital, Irbid
Istanbul Universtesi Istanbul Tip Fakultesi, Çapa
Ege Universitesi Tip Fakultesi Cocuk Hastanesi, Izmir
Dr. Behcet Uz Child and Diseases And Surgery Education and Research Hospital, Izmir
Erciyes Universitesi Tip Fakultesi, Kayseri
Hospital Civil de Guadalajara Dr. Juan I. Menchaca, Guadalajara
Cincinnati Children's Hospital Medical Center, Cincinnati
On Dokuz Mayis University Faculty of Medicine, Samsun
Hospital y Clinica OCA S.A. de C.V., Colonia Centro
"Hospital Universitario Dr. Jose Eleuterio Gonzalez", Monterrey
Childrens Medical Center Dallas, Dallas
University of Utah, Salt Lake City
Primary Children's Hospital, Salt Lake City
OHSU Investigational Pharmacy, Portland
Oregon Health & Science University, Portland
University of Texas Southwestern Medical Center at Dallas, Dallas
Fundacion de la Hemofilia, Buenos Aires
Liga Colombiana de Hemofílicos y otras Deficiencias Sanguíneas, Bogotá
Centro Medico Monte Carmelo, Urbanización La Victoria
Samodzielny Publiczny Dzieciecy Szpital Kliniczny, Warsaw
Sanador, Bucharest
Cukurova University Tip Fakultesi, Balcali/Adana
Akdeniz Universitesi Tip Fakultesi, Antalya
Lead Sponsor
Pfizer
INDUSTRY